Kenvue's shares were down 1.2% in premarket trading. J&J shares were largely unchanged. J&J finalized the biggest shake-up in its 137-year history to focus on its pharmaceutical and medical ...
Johnson & Johnson plans to unload its remaining 9.5% stake in Kenvue in a public offering set about a year after it started splitting off the Tylenol and Benadryl maker. About Dow Jones Newswires ...
(Bloomberg) -- Johnson & Johnson and Kenvue Inc. were ordered to pay $45 million to the family of an Illinois woman who blamed the companies’ baby powders for giving her a fatal cancer in what ...
Kenvue manages a wide array of products within each segment, but sales volume remains vulnerable to consumer spending. See ...
Investing in J&J offers potential dividend income with 61 years of consecutive increases. J&J plans to spin off its consumer division, focusing on pharmaceuticals and medical technology.
There’s a lot of evidence suggesting that spinoff stocks are generally a good idea to watch. Following a split from their parent company, many such firms do well thanks to their efficiency and ...
A group of plaintiffs who claim to have become cancer victims after using Johnson & Johnson's (NYSE:JNJ) talc-based baby powder has filed a lawsuit accusing the company of fraudulently resorting ...
J. Smith-Cameron weighed in on a potential ‘Succession’ spin-off, saying it would be timely, even this soon after the series ...
The "Game of Thrones" universe is expanding. Here's the status of every spinoff, from "A Knight of the Seven Kingdoms" to the ...
Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that ...
(Reuters) -Tylenol maker Kenvue said on Monday that Johnson & Johnson will sell its remaining 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer ...